Interventional - Drug
The objectives of this randomized controlled trial, of individuals with heart failure (HF) secondary to ischemic heart disease, are:
1) To examine the impact of colchicine on the composite outcome of CV death, HF hospitalization, urgent HF visit, cardiac arrest, or ischemic cardiovascular events (define as myocardial infarction, ischemic stroke, or arterial revascularization).
2) To examine the impact of thiamine on the composite outcome of CV death, HF hospitalization or urgent HF visit.
As a 2×2 factorial RCT, the first factorial will randomize participants to colchicine 0.5 mg daily or to placebo.
The second factorial will be a prospective, randomized, open-label, blinded-endpoint (PROBE) design with participants randomized to open-label thiamine 200-300 mg daily or to no thiamine (control).
COLT-HF is one of the studies that is part of the CHF Alliance, a pan-Canadian, patient-driven network of heart failure reseachers.
Interventional - Drug
2x2 factorial RCT
2022 - 2027
Philip Joseph’s research interests include cardiovascular prevention, global health, heart failure, and cardiac imaging. He is the principal investigator for the PURE-AF substudy, and the SPECT-MINS study, an investigator in the PURE study, and the G-CHF registry. He is also the project officer for the TIPS-3 study. He has published more than 30 peer-reviewed scientific papers.
He is a fellow of the Royal College of Physicians and Surgeons of Canada, with certification in both internal medicine and cardiology. obtained his B.A.Sc at McMaster University in 2000, and his M.D. at Western University in 2004. His internal medicine (2004-2007) and cardiology (2007-2010) residencies were completed at the University of Ottawa. Subsequently, he completed additional clinical training in Nuclear Cardiology at McMaster University (2013), a M.Sc. in Health Research Methodology at McMaster (2010-13), and a post-doctoral research fellowship in PET imaging at Harvard University (2015).
Eva Lonn is a Principal Investigator for the Atherosclerosis Imaging and Cardiovascular Prevention programs at PHRI, and a Professor of Medicine in the Division of Cardiology at McMaster University.
She has led several large international trials and was a member of the International Steering Committee of additional landmark cardiovascular prevention trials. She directed the Vascular Research Ultrasound Laboratory at PHRI for more than 20 years. She served for many years on the Canadian Cardiovascular Society Council and Executive Committee. She has received research grants from the Medical Research Council of Canada, the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. She published over 220 peer reviewed articles, and 8 book chapters.
After obtaining her medical degree from the Hebrew University in Jerusalem, Eva Lonn completed clinical training in Internal Medicine, Cardiology and Advanced Imaging at the University of Toronto and research fellowships at the University of Toronto and at McMaster University, where she obtained also a Master of Science degree in Health Research Methodology.
Executive Director; Senior Scientist
Salim Yusuf is an internationally renowned cardiologist and epidemiologist, whose work over 40 years has substantially influenced prevention and treatment of cardiovascular disease. Born in India, medically qualified at St. John’s Medical College, Bangalore in 1976, he received a Rhodes Scholarship and obtained a DPhil from Oxford, during which he (along with Richard Peto, Rory Collins and Peter Sleight) initiated the concepts of large, simple trials, and meta-analysis. He proposed the concept of combination drug treatment for prevention of CVD to achieve large reductions in CVD with a single pill (now called the polypill concept), but more importantly has been evaluating the concept through large randomized trials.
He leads several global studies involving more than 60 countries in every inhabited continent of the world aimed at enhancing knowledge about the biological, behavioural and societal causes, consequences, and approaches to the control of heart diseases, and strokes through large multi-country programs such as INTERHEART, INTERSTROKE, and PURE.
He holds a Heart and Stroke Foundation of Ontario Research Chair and has received (among others) the Lifetime Research Achievement award of the Canadian Cardiovascular Society; the Paul Wood Silver Medal of the British Cardiac Society; the European Society of Cardiology gold medal, the clinical Research Prize of the American Heart Association and the International Award and the Braunwald Lecture of the American College of Cardiology. He has been inducted into the Royal Society of Canada and the Canadian Medical Hall of Fame; been appointed as an Officer of the Order of Canada, and received the Canada Gairdner Wightman Award in 2014. He has received four honorary doctorates, and is among the top 20 most cited health researchers in history.
Salim Yusuf has published more than 1,000 articles in refereed journals, rising to the second most cited researcher in the world for 2011. He has mentored more than 120 scientists, several of whom are in leadership positions across the globe. He has been President of the World Heart Federation (2015-2016), where he initiated several programs (the Emerging Leaders program, road maps for CVD control and a course for training primary care practitioners in CVD prevention) aimed at halving the CVD burden globally within a generation. The World Heart Federation has recognized his contributions by naming the program the Salim Yusuf Emerging Leaders Programme.
He is a Distinguished University Professor of Medicine, and Executive Director of the Population Health Research Institute, McMaster University and Chief Scientist, Hamilton Health Sciences.
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
Amy Krol has been employed by the Population Health Research Institute over the last 19 years where she has worked on a number of large, international, industry-sponsored trails. For the past six years, she has focused her efforts on coordinating site management for the INVICTUS study, an investigator-initiated rheumatic AF trial & registry.
She holds a Bachelor of Science Degree (Honours Biology) from Wilfrid Laurier University and a Clinical Research Associate Certificate from McMaster University.
Divya Pattath has been with the Global Health team at PHRI since 2013, and has experience with managing large, international investigator-initiated clinical trials, observational studies and registries.
Divya holds a Masters Degree in Industrial Biotechnology and Enterprise from University of Bath, UK and Applied Clinical Research Certificate from McMaster University.
Back To Top